Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea...( - Positive results from Pyratine XR(T...)

- Positive results from Pyratine XR(TM) rosacea-specific study also slated for presentation at American Academy of Dermatology Meeting on March 8, 2009 -

NAPA, Calif., March 5 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, announced today that Pyratine XR(TM) is officially launching at the American Academy of Dermatology's 67th Annual Meeting in San Francisco, March 6-10, 2009, at Booth #5736. In addition, positive study results from a clinical trial of Pyratine XR(TM) in patients with rosacea will be presented.

Dr. Arisa Ortiz, Clinical Research Fellow in the Department of Dermatology at the University of California, Irvine, will be presenting the abstract, "Long-term Efficacy and Safety of Topical PRK 124 (0.125%) Lotion (Pyratine XR(TM)) for Improving the Signs and Symptoms of Rosacea," at the March 8th Residents & Fellows Symposium. A highly selective process, 23 abstracts are accepted for oral presentation.

The rosacea-specific study data demonstrated that Pyratine XR(TM) showed continual improvement for all of the major symptoms of rosacea - redness, lesions and spider veins - throughout the entire course of 48-week treatment period. This suggests that Pyratine XR(TM) may offer important advantages over currently available treatments for rosacea, many of which have issues with long-term tolerability. Since rosacea is a chronic condition that often requires extended treatment periods with topical agents that can cause high skin sensitivity, treatments that provide sustained relief of the signs and symptoms of rosacea are needed.

Eighteen subjects with mild-to-moderate rosacea participated in a 48-week clinical trial at the University of California, Irvine, to assess the effects of Pyratine XR(TM) (0.125% furfuryl tetrahydropyr
'/>"/>